Keywords: glucagon-like peptide 1 receptor agonists, semaglutide, salivary glands, xerostomia, cyclic AMP, beta-arrestins Abstract This review addresses the growing concern of oral side effects, particularly dry mouth, associated with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used for diabetes and obesity
In some cases, both claims can be pursued together
100 percent subcutaneous | | Reported weight data | 12.4 % (36 mg, 72 wk, ATTAIN-1) | 24.2 % (12 mg, 48 wk, Phase 2) | | Food restriction | None | Not applicable | | Status | FDA-approved (Foundayo, April 2026) | Research substance, not approved | The table illustrates that the higher weight values of retatrutide result from a broader receptor activation and the injection-driven complete entry of the active substance, while orforglipron has its strength in ease of administration and oral availability
Patients lose fat in the cheeks, temples, and jawline faster than the skin can adapt, creating a gaunt or hollow appearance even when their body weight and overall health have improved significantly
Not valid for cash or cash equivalent
